Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Vesterbacka

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Plos One|December 29, 2023
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trialJonas Sundén-Cullberg, Puran Chen, Henrike Häbel, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Cell Host & Microbe|January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variantThomas R Müller, Yu Gao, Jinghua Wu, et al.
Science Translational Medicine|July 12, 2023
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised statesThomas R Müller, Takuya Sekine, Darya Trubach, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
Immunity|August 12, 2022
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccinationYu Gao, Curtis Cai, David Wullimann, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Plos One|December 29, 2023
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trialJonas Sundén-Cullberg, Puran Chen, Henrike Häbel, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Cell Host & Microbe|January 11, 2024
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variantThomas R Müller, Yu Gao, Jinghua Wu, et al.
Science Translational Medicine|July 12, 2023
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised statesThomas R Müller, Takuya Sekine, Darya Trubach, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
Immunity|August 12, 2022
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccinationYu Gao, Curtis Cai, David Wullimann, et al.
Pageof 4